NCAPG promotes the malignant progression of endometrioid cancer through LEF1/SEMA7A/PI3K-AKT
2025

NCAPG and Its Role in Endometrioid Cancer Progression

Sample size: 84 publication Evidence: high

Author Information

Author(s): Ren Zhen, Li Xiaohan, Fu Chun

Primary Institution: The Second Xiangya Hospital of Central South University

Hypothesis

NCAPG promotes the malignant progression of endometrioid cancer through the LEF1/SEMA7A/PI3K-AKT pathway.

Conclusion

The study confirms that NCAPG enhances SEMA7A transcription, activating the PI3K/AKT pathway and promoting cancer cell proliferation, migration, and invasion.

Supporting Evidence

  • NCAPG enhances the transcription of SEMA7A by modulating the chromatin accessibility of the transcription factor LEF1.
  • SEMA7A binds to the PI3K regulatory subunit p85, activating the PI3K-AKT signaling pathway.
  • High expression of LEF1 and SEMA7A correlates with advanced FIGO stage and myometrial invasion in endometrial cancer patients.

Takeaway

This study shows that a protein called NCAPG helps cancer cells grow and spread by affecting other proteins that control cell behavior.

Methodology

The study used ATAC-Seq, qRT-PCR, and Co-Immunoprecipitation to analyze the effects of NCAPG on endometrioid cancer cells.

Participant Demographics

Patients diagnosed with endometrioid carcinoma, with no prior hormonal therapy, radiotherapy, or chemotherapy.

Statistical Information

P-Value

1.00E-15

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.7150/jca.100951

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication